Equities researchers at Aegis assumed coverage on shares of Xtant Medical Holdings Inc (NASDAQ:XTNT) in a research report issued on Wednesday. The firm set a “buy” rating on the stock.

A number of other equities analysts have also commented on XTNT. HC Wainwright reaffirmed a “buy” rating on shares of Xtant Medical Holdings in a research report on Thursday, August 4th. Zacks Investment Research upgraded shares of Xtant Medical Holdings from a “sell” rating to a “hold” rating in a research note on Tuesday, August 30th.

Shares of Xtant Medical Holdings (NASDAQ:XTNT) opened at 0.4935 on Wednesday. Xtant Medical Holdings has a 1-year low of $0.45 and a 1-year high of $3.75. The company’s 50 day moving average is $0.76 and its 200-day moving average is $1.44. The company’s market capitalization is $6.02 million.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/30/aegis-initiates-coverage-on-xtant-medical-holdings-inc-xtnt.html.

Xtant Medical Holdings Company Profile

Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.

5 Day Chart for NASDAQ:XTNT

Receive News & Stock Ratings for Xtant Medical Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical Holdings Inc and related stocks with our FREE daily email newsletter.